The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: Significant lessons from a dual graft case

American Journal of Transplantation

Volumn 11, Issue 6, 2011, Pages 1325-1329

  Motomura, T ^a   Taketomi, A ^a   Fukuhara, T ^a,b   Mano, Y ^a   Takeishi, K ^a   Toshima, T ^a   Harada, N ^a   Uchiyama, H ^a   Yoshizumi, T ^a   Soejima, Y ^a   Shirabe, K ^a   Matsuura, Y ^b   Maehara, Y ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Dual grafts; hepatitis C; IL28B; liver transplantation

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BILE DUCT RECONSTRUCTION; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENETIC VARIABILITY; GENOTYPE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOJEJUNOSTOMY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REINFECTION; RELAPSE; RNA EXTRACTION; SIDE EFFECT; VIRUS LOAD;

EID: 79958792857     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03537.x     Document Type: Article

References (20)

1. Brown RS,. Hepatitis C and liver transplantation. Nature 2005; 436: 973-978.
2. Angelico M, Petrolati A, Lionetti R, et al,. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplants recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-1017. (Pubitemid 46680357)
3. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
4. Fukuhara T, Taketomi A, Motomura T, et al,. IL28B variation in recipients and donors associates with response to Peginterferon/ribavirin for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.
5. Gao B, Hong F, Radaeva S,. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004; 39: 880-890. (Pubitemid 38428923)
6. Walsh MJ, Jonsson JR, Richardson MM, et al,. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529-535.
7. Fukuhara T, Taketomi A, Okano S, et al,. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol 2010; 52: 672-680.
8. Soejima Y, Taketomi A, Ikegami T, et al,. Living donor liver transplantation using dual grafts from two donors: A feasible option to overcome small-for-size graft problems? Am J Transplant 2008; 8: 887-892. (Pubitemid 351347761)
9. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-293. (Pubitemid 26260021)
10. Sherman M, Yoshida EM, Deschenes M, et al,. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006; 55: 1631-1638 (Pubitemid 44629215)
11. Ramirez S, Perez-Del-Pulgar S, Carrion JA, et al,. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant 2009; 9: 1591-1601.
12. Grebely J, Petoumenos K, Hellard M, et al,. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224
13. Honda M, Sakai A, Yamashita T, et al,. Hepatic Interferon-stimulated genes expression is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic Hepatitis C. Gastroenterology 2010; 139: 499-509.
14. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al,. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039. (Pubitemid 351754525)
15. Chen L, Borozan I, Sun J, et al,. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastoroenterology 2010; 138: 1123-1133.
16. Broering R, Zhang X, Kottilil S, et al,. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 2010; 59: 1111-1119.
17. Soejima Y, Taketomi A, Yoshizumi T, et al,. Biliary strictures in living donor liver transplantation: Incidence, management, and technical evolution. Liver Transpl 2006; 12: 979-986. (Pubitemid 43964466)
18. Cescon M, Grazi GL, Cucchetti A, et al,. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-789.
19. Wali M, Harrison RF, Gow PJ, Mutimer D,. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-252. (Pubitemid 34791456)
20. Jiménez-Pérez M, Sáez-Gõmez AB, Pérez-Daga JA,. Hepatitis C virus recurrence after liver transplantation: Analysis of factors related to sustained viral response. Transplant Proc 2010; 42: 666-668.